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A  partially  purified preparation  of calf thymus extract  (THF)  1 has  been 
shown by  us  to  participate  in  the  processes which lead  to  maturation and 
acquisition of immunocompetence of mouse thymus-derived lymphoid cells (1, 
2). The specific capacity of THF to restore the immunocompetence  of lymphoid 
cells from neonatally thymectomized (NTx) animals or to induce maturation of 
thymus-derived lymphoid cell populations has been demonstrated by a variety 
of bioassays.  For example, THF was shown to improve the competence of T 
lymphocytes  to participate in mixed lymphocyte (3) and graft-versus-host (GvH) 
(4) reactions, to increase their reactivity to T lectins (5) and to augment their 
capacity to kill tumor cells (6). The activity of THF was also confirmed in vivo, 
since  single  or  repeated  injection  of this  material  increased  the  T-helper 
capacity  of cells  in  the  antibody  response  against  sheep  erythrocytes (7), 
restored the GvH reactivity of spleen cells from NTx mice (4), and raised the 
anti-tumor reactivity of lymphocytes  obtained from tumor-bearing mice against 
syngeneic  tumors.  2  Moreover, it was demonstrated recently  that the administra- 
tion  of THF  to  humans  suffering either  from  primary  or  from  secondary 
immunodeficiencies resulted in the restoration of cellular immunocompetence, 
while progressive clinical improvement of these patients was observed (8-11). 
Immune maturation of thymus-derived lymphoid cells, after in vitro (12, 13) or 
in vivo  3 exposure to THF occurs via an obligatory rise in cellular cAMP levels, 
thus establishing the hormonal nature of THF in agreement with the criteria 
postulated by Sutherland (14). 
The above results justified further studies performed in our laboratory to 
purify and characterize the active component of THF responsible for the effects 
described. THF was isolated by a procedure which consisted in a stepwise gel 
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filtration through Sephadex columns. When tested in terms of the acquisition of 
competence by spleen cells from NTx mice in an in vitro assay of GvH reactivity 
it appeared that the pure material of THF is a polypeptide of 3,000 mol wt which 
migrates  as  a  single  band  in  iso.electric focusing and  sodium dodecyl sulfate 
polyacrylamide gel electrophoresis  (15).  Amino  acid analysis of acid hydroly- 
zates revealed that  purified THF contains approximately  30 residues.  At this 
point of our investigations it was necessary to test whether this active compo- 
nent  of THF  is responsible for all  the  biological  activities obtained with the 
crude material  (2).  Such a  screening of activities with the pure THF material 
was  also  felt  necessary,  since  Hooper  et  al.  reported  that  thymosin  a~,  a 
chemically  defined  peptide  isolated  from thymosin  fraction  5  (16),  was more 
active in certain respects than the cruder fraction, while a  loss of activity was 
manifest  in  other tests  (17).  This  suggested that  in  addition  to thymosin  al, 
fraction  5  contained  other  components  necessary  to  elicit  full  immunologic 
reactivity. 
In the present experiments THF was administered either in vitro or in vivo 
and  its activity was tested by a  second in vitro assay of immune competence 
(mixed  lymphocyte  culture)  and  by  an  in  vivo  GvH  assay  in  addition  to 
measurements of cAMP levels in the cells examined. The results presented here 
suggest  that  one  single  peptide  with  the  chemical  characteristics  described 
previously is responsible for endowment of reactivity to T cells which participate 
in  cell-mediated  immunity.  Moreover,  this  final  active  peptide  obtained  by 
stepwise purification was found to be 2 x  104-fold more active than the dialyzate 
of crude thymus extract which served as a starting material. 
Materials  and Methods 
Mice.  Newborn C57BL/6 and 6- to 8-wk old C57BL/6 and (C3H/eb  x  C57BL/6)FI hybrids of 
both sexes were used in the present experiments. Thymectomy was performed within 24 h  after 
birth. Animals found to contain a thymic remnant were discarded from the experiments. (C3H/eb 
x  C57BL/6)F1 newborn mice served as hosts for the in vivo GvH assay. 
Preparation of Cell Suspensions.  Spleens or thymuses from 6- to 8-wk old mice were removed 
aseptically and gently dispersed through a  stainless steel mesh and the cells were suspended in 
Eagle's medium (EM), supplemented with penicillin 100 U/ml, and streptomycin 100 ~g/ml. Cells 
were washed twice in EM and counted in Turk solution with a hemocytometer. Exclusion of 0.05% 
trypan blue solution was used as a measure of viability. 
Preparation of Organ Extracts.  THF was prepared from calf thymus. The standard prepara- 
tion of crude dialyzates consisted in homogenization, ultracentrifugation, and exhaustive dialysis 
of the material. The dialyzate obtained was stored at  -20°C  (4,  15).  No cAMP or DNA could be 
detected  in the thymic preparations  (15).  In contrast to  proteolytic digestion treatment of the 
thymus extract  with RNase  did not abolish its activity  (15).  Thus the concentration of active 
material used in the present experiments is expressed as protein per milliliter. The more purified 
fractions of THF were prepared as described (15). Spleen extracts were prepared in a way identical 
to that of thymus extract (4).  In addition to spleen extracts the following substances were tested 
as controls: glucagon (Sigma Chemical Co., St. Louis, Mo.), bovine serum albumin (BSA) (Sigma 
Chemical Co.), phosphate-buffered saline 0.05 M (PBS). 
Biological Assays for Testing the Activity of THF and other Control Materials.  The various 
fractions obtained during the process of purification of THF as well as control materials were 
tested in the following in vitro and in vivo assays. 
cAMP Determination 
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fractions of THF for 5 rain at 37°C  in water bath. The cells were washed three times with large 
volumes of PBS and intracellular cAMP content was determined. 
IN vivo TREATMENT.  The various purified THF fractions or each of the control materials were 
injected im into 4  wk  old C57BL/6  NTx mice daily  for  14 days.  At the  15th-day spleens were 
removed and their cellular cAMP content was determined. 
Assay.  Intracellular cAMP was measured by a slight modification of Gilman's procedure (18). 
The cells were spun in the cold, the supernate was removed, and 0.1 ml of 0.1 N  HCI was added. 
The samples were placed in an 80°C water bath for 3 rain and then immediately transferred to an 
ice water bath and neutralized to pH 7.5 by 0.25 M Tris/20 mM EDTA buffer pH  12.3.  Cellular 
levels of cAMP  were  determined  with the  cAMP  kit  provided  by  the  Radiochemical  Centre, 
Amersham, England (Code TRK, 432). 
Mixed Lymphocyte Culture (MLC) Assay 
IN  VITRO TREATMENT.  107  Spleen  cells  from  intact and  NTx  6  wk  old  C57BL/6  mice  were 
preincubated  with the  various  purified  THF  fractions  for  1  h,  and  washed  twice  with  large 
volumes of EM before the antigenic stimulation in the MLC assay. 
IN VIVO TREATMENT.  Spleen cells from 6 wk old NTx C57BL/6 mice injected i.m.  during 14 
days with the various purified THF fractions or with the control materials were assayed for their 
ability to react in the MLC assay. 
Assay.  The  experiments  were  carried  out  in  Falcon  2058  12  x  75-mm  tubes  with  caps 
(BioQuest,  BBL  &  Falcon  Products,  Cockeysville,  Md.).  Cells  were  suspended  in  RPMI-1640 
medium (Grand Island Biological Co.,  Grand Island, N.  Y.), buffered with sodium bicarbonate, 
and supplemented with penicillin 100  U/ml,  streptomycin 100  ~g/ml,  and 5% heat-inactivated 
fetal  bovine  serum  (Rehatuin,  Reheis  Chemical  Co.,  Chicago,  Ill.).  Stimulating  spleen  cells 
from intact C57BL/6 or (C3H/eb  ×  C57BL/6)F1 mice were brought to a  concentration of 1  ×  l0  T 
cells/ml and incubated with 25 ~g/ml mitomycin-C (Sigma Chemical Co.) at 37°C for 30 min. The 
cells were then washed three times in a  large volume of EM and brought to a  concentration of 2 
×  106 cells/ml RPMI-1640 medium.  0.5 ml Containing 106 cells was added to the Falcon tubes. 
Responding spleen cells either from intact or from NTx mice were also brought to a concentration 
of 2 ×  106/ml and 0.5 ml containing 106 cells was added to the tubes. The tubes were capped, mixed 
lightly, and incubated at 37°C in a humidified incubator in an atmosphere of 95% air and 5% CO~. 
72 h  after the initial time of incubation 2 ~Ci of tritiated thymidine (Amersham, Buckingham- 
shire, England) sp act of 5 Ci/mmol was added in 50 ~1 of RPMI medium.  18 h  later cells were 
removed, washed with saline, and precipitated with 5% trichloroacetic acid on a  Whatman glass 
fiber filter GF/A  size  1.5  ×  19.5 cm  (W.  and  R.  Balston,  Ltd.,  England).  Filters  were  put in 
scintillation  vials  with  simultaneous  addition  of 10  ml  scintillation fluid  and  the  cpm  were 
monitored. Triplicate cultures were used for each group in each experiment. The proliferation of 
spleen cells from parental  C57BL/6  mice stimulated by mitomycin-C-treated spleen cells from 
(C3H/eb ×  C57BL/6)F1 mice was compared to the degree of proliferation exhibited by the parental 
spleen cells in the presence of syngeneic spleen cells treated with mitomycin-C.  As previously 
indicated (19) the data are expressed as an increase in net cpm. 
In Vivo GvH Assay.  Spleen cells from 6 wk old NTx C57BL/6 mice injected i.m.  daily with 
each of the various THF fractions or each of the control materials were brought to a concentration 
of 3  ×  106 in 0.05 ml PBS and injected intraperitoneally into 1 day old (C3H/eb  ×  C57BL/6)F1 
mice.  Recipient litters included mice injected with each type of donor cell as well as uninjected 
controls. The recipients were sacrified 10 days after challenge and the ratio of mg spleen: 10 g body 
weight was measured according to the method of Simonsen et al.  (20). Spleen index was obtained 
by dividing the spleen:body weights by the corresponding value of the injected control animals, 
since spleen weight of uninjected controls is equivalent to mice injected with syngeneic cells (4). 
Statistical Analysis.  The Student's t test was used to analyze the statistical significance of the 
results. Results are expressed as mean _+ standard error. 
Results 
We have recently reported the procedure of isolation of THF as outlined in 
Fig. 1. The partially purified dialyzate of the thymus extract (4, 15) was further 74  INCREASED  REACTIVITY  OF  THYMIC  HORMONE 
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Fro.  1.  Procedure for isolation of the active component of THF from calf thymus.  A. The 
elution  pattern  of the dialyzate obtained  from supernate  of homogenized  calf thymus  on 
Sephadex  G-10 columns.  Shaded  area represents  activity  eluted  from the column  in the 
void volume.  B. The elution pattern of the active peak obtained from A  on Sephadex G-25 
superfine column.  Shaded area represents activity eluted from this column.  C. The elution 
pattern of the active peak obtained from B  on DEAE  Sephadex A-25 column.  The column 
was equilibrated with 0.1 M NH4HCO3 pH 8.0 buffer and the material eluted with a linear 
gradient of NaC1. Shaded area represents activity eluted from the column. 
fractionated by gel filtration through a Sephadex G-10 column and the activity 
checked by the in vitro GvH assay was recovered in the void volume (Fig.  1 A). 
The void volume active fraction (hereafter fraction A) was further fractionated 
by  gel  filtration  on  a  Sephadex  Go25  superfine  column  and  activity  (again 
measured by GvH in vitro assay) was consistently found in one peak only (Fig. 
1 B).  The  active  fraction  eluted  from  the  Sephadex  G-25  column  (hereafter 
fraction B) was then fractionated by anion exchange chromatography on DEAE 
Sephadex A-25 column. The biological activity measured as before was concen- 
trated  in  one  peak,  eluted  at  0.15  M  NaC1  (Fig.  1C).  This  material  is 
represented by one active peptide (hereafter fraction C) with an isoelectric point 
(PI) of 5.6 (15). The in vitro GvH assay which was used throughout the purifica- 
tion procedure described is characterized by an all or none type of response.  It 
was therefore of cardinal importance to use other biological assays to estimate 
the enrichment of biological  activities obtained with the various purified THF 
fractions. 
Enrichment of Biological  Reactivity  of THF Fractions  by Their Progressive 
Purification  as  Measured  by  the  MLC Assay.  Spleen  cells  from  NTx  mice 
exhibit a reduced capacity to respond in the MLC assay (21, 22) and this could YESHAYAHU  YAKIR,  ABRAHAM  I.  KOOK,  AND  NATHAN  TRAININ 
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Fro.  2.  In vitro effect of different concentrations  of the various active THF fractions on 
the activity of spleen cells from both intact and NTx C57BL/6 mice in the MLC assay,  a. 
Dialyzate  of crude  thymus  extract,  b.  Active  peak  eluted  from  Sephadex  G-10  column 
(fraction A).  c.  Active  peak eluted  from Sephadex  G-25 superfine column  (fraction B).  d. 
Active peak eluted from DEAE Sephadex A-25 column (fraction C). Spleen cells from intact 
mice  (O  i)  and NTxmice  (©  ..... ©).  Bars represent  mean of triplicate  samples  ±  SE. 
Data represent one out of five such experiments. 
be restored by pretreatment with the partially purified dialyzate of THF (3). We 
studied  here  whether  the  various THF fractions  isolated by further  stepwise 
purification  could  also  restore  the  impaired  MLC  response.  In  parallel,  the 
effect of the various THF fractions was also checked on spleen cells from intact 
mice. Spleen cells from NTx mice were first preincubated with the various THF 
fractions  (fractions  A,  B,  and C) in different protein concentrations  and then 
submitted to the MLC test. As can be seen (Fig. 2 a-d) cell reactivity was raised 
to a level similar to that of normal spleen cells.  Moreover, fractions A, B, and C 
significantly increased the response of spleen cells from intact mice above that 
of untreated  controls.  We  also  observed  that  a  progressively  lower  protein 
concentration  was required  for the  induction of maximal  MLC  augmentation 
where more purified fractions were studied. Thus, as can be seen in Fig. 2, 0.005 
/~g protein  of fraction  C  was  equivalent  to  0.1  /~g of fraction  B,  to 20  /~g of 
fraction A, or to 80/~g of dialyzate of crude thymus extract.  A parallel can also 76  INCREASED  REACTIVITY  OF  THYMIC  HORMONE 
TABLE  I 
The in Vitro Effect of the Active Fractions Obtained during the Process of 
Stepwise Isolation of THF on the IntraceUular cAMP Levels in Thymocytes 
from C57BL/6 Mice 
Fractions  Optimal THF dose 
~g/ml 
m 
Dialyzate of crude thymus extract  80 
Void volume  fraction  of Sephadex  20 
G10 column (fraction  A) 
Active peak of Sephadex G-25 col-  0.1 
umn (fraction  B) 
Active peak of DEAE Sephadex A-  0.005 
25 column (fraction  C) 
pmol of cAMP +- SE*/IO  7 
thymocytes 
1.2 _ 0.30 
4.2 +_ 0.75 
4.5 +- 0.80 
4.1 +_ 0.80 
3.9 ~- 0.70 
* Data represent one out of five such experiments. Each experiment was done in 
triplicate. SE = Standard error. 
be seen between the increasing concentrations of the respective fractions tested 
and the MLC response which reaches a plateau after a certain point. It should 
be stressed that each of the peaks obtained during the stepwise purification of 
THF fractions (A, B, and C) which were found inactive in the in vitro GvH test, 
were also tested in the MLC assay. Each of these inactive peaks was also devoid 
of activity in this assay. 
Increase of Intracellular cAMP Levels in Thymocytes by Progressively Lower 
Concentrations of THF Fractions A, B, and C.  Intracellular levels of cAMP 
were measured in thymus cells rather than in spleen cells since they represent 
a more homogeneous lymphoid cell population. Furthermore, thymus cells are 
known to  exhibit low  levels  of cellular cAMP  (Kook,  A.  I.,  Yakir,  Y.  and 
Trainin, N., unpublished results) thus permitting us to study the in vitro effect 
of the various purified fractions of THF. Exposure of thymus cells for 5 min to 
the various THF fractions was followed by an increase in the cAMP level of 
these cells (Table I). Moreover the activity of  fractions A, B, and C, respectively, 
was equal to increasingly reduced doses. Thus, 0.005 ~g protein of fraction C 
was equivalent to 0.1  ~g of fraction B, to 20  ~g of fraction A, or to 80  ~g of 
dialyzate  of crude  thymus  extract.  A  striking  finding  was  the  similarity 
between the pattern of the MLC response and the cellular cAMP levels observed 
with  progressively purified  THF  fractions.  Peaks  of fraction  A,  B,  and  C, 
inactive in the in vitro GvH and MLC assays were also devoid of activity in the 
intracellular cAMP assay. 
The in Vivo Effect of THF Fractions on the Restoration of  lmmunocompetence 
of Neonatally  Thymectomized  Mice.  At  this  point  in  the  investigation  it 
seemed  to  us  essential  to  determine  whether  the  increased  immunological 
reactivity obtained with the various purified THF fractions in vitro could also 
be observed in vivo. For this purpose 4 wk old C57BL/6 mice thymectomized at 
birth were injected with 0.1 ml of each of the THF fractions containing different 
amounts of protein diluted in PBS. On the 15th-day after 14 daily i.m. injection, 
cell  suspensions  were  prepared  from  the  spleen  of these  animals  and  the YESHAYAHU  YAKIR,  ABRAHAM  I.  KOOK,  AND  NATHAN  TRAININ  77 
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FIG.  3.  Effect of repeated injections of active THF fractions on the capacity of spleen cells 
from NTx C57BL/6 mice to elicit an in vivo GvH response upon inoculation into newborn 
(C3H/eb  ×  C57BL/6)F1 mice. a. Spleen cells from normal 2 mo old (C57BL/6  ×  C3H/eb)F~ 
mice inoculated into syngeneic (C57BL/6  ×  C3H/eb)FI newborn mice. b. Spleen cells from 
NTx 2 mo old C57BL/6 mice inoculated into syngeneic C57BL/6 newborn mice. c.  Spleen 
cells  from  NTx  2  mo old  C57BL/6  mice  injected  14  times with  40  ~g protein/mouse of 
dialyzate of crude thymus extract inoculated  into syngeneic C57BL/6  newborn mice.  d. 
Spleen cells from NTx 2 mo old parental C57BL/6 mice inoculated into (C57BL/6  ×  C3H/ 
eb)Fl newborn mice. e.  Spleen cells from NTx 2 mo old parental C57BL/6 mice injected 14 
times  with  40  ~g  protein/mouse  of dialyzate  of crude  thymus  extract  inoculated  into 
(C57BL/6  x  C3H/eb)F~ newborn mice. f. Spleen cells from NTx 2 mo old parental C57BL/6 
mice injected 14 times with 10/~g protein/mouse of fraction A inoculated into (C57BL/6  × 
C3H/eb)FI newborn mice. g. Spleen cells from NTx 2 mo old parental C57BL/6 mice injected 
14 times with 0.1  ~g protein/mouse of fraction B  inoculated into  (C57BL/6  ×  C3H/eb)F~ 
newborn mice. h. Spleen cells from NTx 2 mo old parental C57BL/6 mice injected 14 times 
with 0.002 ~g protein/mouse of fraction C inoculated into (C57BL/6  ×  C3H/eb)FI newborn 
mice. i. Spleen cells from 2 mo old parental intact C57BL/6 mice inoculated into (C57BL/6 
×  C3H/eb)F~  newborn  mice.  Bars  represent  mean  of  triplicate  samples  ±  SE.  Data 
represent one out of five such experiments. 
immunocompetence of the cells was simultaneously evaluated  by the in vivo 
GvH  assay  and  by  the  mixed  lymphocyte  reaction.  In  addition,  changes  in 
intracellular cAMP was measured in these cells. 
In  Vivo GvH.  Dissociated spleen cells  (3  ×  106/0.05 ml of PBS) from NTx 
C57BL/6 mice treated with the THF fractions A, B, or C, or control spleen cells 
from both NTx and intact C57BL/6 mice were injected into 1- to 2-day-old  (C3H/ 
eb  x  C57BL/6)F1 hybrids  and the index of splenomegaly  determined  10 days 
later according to the assay of Simonsen et al.  (20). Splenomegaly induced by 
cells from NTx-treated mice was significantly higher than that induced by cells 
of control  thymectomized  mice  and  reached  a  level  similar  to that obtained 
when normal spleen cells were injected. Moreover, the restoration of immuno- 
competence observed  here  by the injection of the various THF fractions was 
similar to that obtained above by the in vitro incubation of spleen cells with the 
same fractions. As can be seen in Fig. 3, treatment with daily injection of 0.002 
/~g of fraction C restored the capacity of C57BL]6 NTx mice to induce in (C3H! 
eb  x  C57BL/6)F1 newborn recipients an index of splenomegaly similar to that 
obtained by treatment of 0.1/~g of fraction B, 10/~g of fraction A, or 40/~g of the 
dialyzate of thymus extract. 
Mixed Lymphocyte Reaction.  Spleen cells obtained from NTx mice injected 
with THF fractions A, B, or C and from uninjected NTx or intact C57BL!6 mice 78  INCREASED  REACTIVITY  OF  THYMIC  HORMONE 
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Fio.  4.  The effect of repeated injections of active THF fractions on the capacity of spleen 
cells from NTx C57BL/6 mice to react in the MLC assay, a. Spleen cells from NTx 2 mo old 
parental C57BL/6 mice. b. Spleen cells from NTx 2 mo old parental C57BL/6 mice injected 
14 times with 40/~g protein/mouse of dialyzate of crude thymus extract before MLC test. c. 
Spleen cells from NTx 2 mo old parental C57BL/6 mice injected 14 times with 10/~g protein/ 
mouse of fraction A, before MLC test. d. Spleen cells from NTx 2 mo old parental C57BL/6 
mice injected 14 times with 0.1 ~g protein/mouse of fraction B before MLC test. e. Spleen 
cells from NTx 2 mo old parental C57BL/6 mice injected  14 times with 0.002 ~g protein/ 
mouse of fraction C before MLC test. f. Spleen cells from 2 mo old parental intact C57BL/6 
mice. Bars represent mean of triplicate samples _+ SE. Data represent one out of five such 
experiments. 
were tested for their ability to respond in the  MLC assay.  It is worthwhile  to 
emphasize that the cells tested here were portions of the cell populations used 
for the  in  vivo  GvH test  described  above and  for the  experiments  on  cAMP 
determination described below. 
As  seen  in  Fig.  4,  spleen  cells  from  NTx  mice  exhibited  a  low  level  of 
reactivity. Injection of the various THF fractions into NTx mice augmented the 
ability  of their  spleen  cells  to  respond  in  the  MLC  assay.  Moreover,  this 
response was raised to  a  level similar to that obtained with spleen cells from 
intact mice. Again the biological reactivity of the various purified THF fractions 
injected increased progressively with THF purification. 
Measurement of  IntraceUular Levels of cAMP.  As it is known from previous 
experiments (13, 14) and also seen above,THF stimulates adenyl cyclase activity 
and  increases  intracellular  cAMP  levels in  lymphoid cells  after a  very short 
incubation.  It is of interest to determine whether in those spleen cells obtained 
from NTx mice treated with the various THF fractions and thus having gained 
higher  levels of immunocompetence,  the  intracellular  levels  of cAMP  would 
also be augmented.  As seen in Table II the basal cellular cAMP levels of spleen 
cells  from  NTx  mice  are  lower  than  those  of spleen  cells  from  intact  mice. 
Injection  of the  various  THF  fractions  into  NTx mice  raised  cAMP  levels of 
spleen cells to  a  level even higher  than that  of intact  mice.  Using the  cAMP 
assay, although there was a  slighter increase with fractions B  and C, we could 
estimate  the  degree  of purification  of the  purified  THF  fractions,  since  the 
pattern was similar to that observed by the immunological GvH and MLC tests. 
Specificity  of  the  in  Vivo  Effect  of THF.  Along  with  these  studies  of 
purification  it was essential to establish the specificity of activity observed by YESHAYAHU  YAKIR,  ABRAHAM  I.  KOOK,  AND  NATHAN  TRAININ  79 
TABLE  II 
The in Vivo Effect of Various Active THF Fractions on the IntraceUular cAMP Levels 
in Spleen Cells from NTx C57BL/6 Mice 
Fractions  Spleen cells  Optimal THF dose 
pmol of  cAMP ± SE*/IO 7 
lag~mouse  spleen cells 
-  NTx  -  2.9 ±  0.45 
Dialyzate of crude thymus extract  NTx  40  6.5 ± 0.80 
Void  volume fraction of Sephadex  G-10 column  NTx  10  7.1 ± 0.90 
(fraction A) 
Active peak of Sephadex G-25 column  (fraction  NTx  0.1  5.9 ±  0.55 
B) 
Active  peak  of DEAE  Sephadex  A-25  column  NTx  0.002  5.8 ±  0.60 
(fraction C) 
-  Normal  -  5.2 ± 0.45 
t.  ic~ 
GVH  MLC 
* Data represent one out of five such experiments. Each experiment was done in triplicate. SE = Standard error. 
a  b  c  d  e  f  g  o  b  c  d  e  f  g 
FIG. 5.  Specificity of the in vivo effect of the dialyzate of crude thymus extract  and of 
THF fraction C on spleen cells from NTx C57BL/6 mice measured by in vivo GvH and in 
vitro MLC assays, a. Spleen cells from NTx C57BL/6 mice. b. Spleen cells from NTx C57BL/ 
6 mice injected 14 times with 40 /~g BSA/mouse. c. Spleen cells from NTx C57BL/6 mice 
injected 14 times with  40 ~g protein  of spleen extract/mouse,  d.  Spleen cells from NTx 
C57BL/6 mice injected 14 times  with  10 ng glucagon/mouse, e.  Spleen cells from NTx 
C57BL/6 mice injected 14 times  with  40 ~g protein/mouse of dialyzate of crude thymus 
extract,  f. Spleen cells from NTx C57BL/6 mice injected 14 times with 10 ng protein/mouse 
of THF fraction C. g. Spleen cells from NTx C57BL/6 mice injected 14 times with  10 ng 
protein/mouse of peak II (inactive) obtained from DEAE Sephadex A-25 column. The in 
vivo GvH and MLC assays were performed as described in Fig. 3 and 4. Bars represent 
mean of triplicate samples _ SE. Data represent one out of five such experiments. 
the stepwise process employed. Therefore, in each of the experiments described 
above,  control  materials  were  tested  in  amounts  equivalent  to  those  of the 
dialyzate of crude thymus extract and to fraction C.  As representative of these 
control  experiments,  Fig.  5  shows  the  results  when  these  materials  were 
injected into NTx mice and the spleen cells of these animals tested  in vivo in 
the  GvH model  and  in  vitro  in  the  MLC  assay.  Control materials  were:  (a) 
spleen extract 40/~g protein daily; (b) BSA 40/~g protein daily, both (a) and (b) 
as controls for dialyzate crude thymus extract;  (c) glucagon,  (mol wt 3,460) as a 
peptide control of a  similar molecular size to fraction C of THF; and (d) peak II 
obtained from DEAE Sephadex A-25 column found to be inactive in the in vitro 80  INCREASED  REACTIVITY  OF  THYMIC  HORMONE 
tests. No activity whatsoever was shown by any of the controls tested. Therefore 
these  experiments  lead  us  to  conclude  that  our  purification  procedure  was 
adequate to isolate the active component of THF. 
Discussion 
We have recently described the process of isolation of the active principle of 
thymus  extract  (THF)  consisting  of homogenization,  ultracentrifugation,  di- 
alysis, and stepwise filtration of the crude material through Sephadex columns 
of different sizes (15).  The bioassay used to monitor these procedures consisted 
of measurement  of the  capacity of the  various  purified  fractions  obtained to 
restore the immunological impairment of spleen cells from NTx mice to induce 
an in vitro GvH response. Since this bioassay is an all or none type of response 
it  was  necessary  to  introduce  more  adequate  tests to quantitate  the  level of 
immunocompetence acquired by the responding cells.  It was also necessary to 
test whether the purified material was active upon injection in vivo. To serve 
these  purposes the  in  vitro  mixed  lymphocyte reaction  and  the  in  vivo GvH 
assay were used after in vitro or in vivo treatment of the cells with the various 
fractions  obtained  during  the  purification  of THF.  In  addition  intracellular 
cAMP levels were measured in the target cell populations, since they correlate 
with the level of immune competence of these cells. 3 
The  results  described here  suggest that  the procedures used permitted  the 
isolation  of active  fractions  (A,  B,  or  C)  progressively  more  active  than  the 
original dialyzate tested. Thus results with the three present assays are parallel 
and confirm the previous results. Moreover, progressively lower protein concen- 
trations  of fraction A,  B, or C  manifested equivalent activity as measured  in 
vitro after preincubation  of target cells from both intact and NTx mice. Thus, 
the DEAE Sephadex A-25 fraction of THF (fraction C) was estimated to be 1 x 
104-2  x  104-fold more active than  the crude dialyzate of thymus extract.  The 
fact that equal concentrations of the various fractions tested produced similar 
effects on the immunological reactivity as well as in the rise of cellular cAMP of 
the  lymphoid  cells  studied,  gives  further  strength  to  our  hypothesis  that 
intracellular  cAMP  participates  in  the  kinetics  involved  in  lymphoid  cell 
maturation.  Moreover,  the  fact  that  restoration  of  immunocompetence  is 
observed after in vitro or in vivo treatment of lymphoid cell populations before 
their  antigenic  stimulation,  points  to  the  physiological  role  of THF  in  the 
differentiation of thymus-derived cells. During the performance of these exper- 
iments particular  attention was given to verifying the specificity of the effects 
obtained with the various active THF fractions. Spleen extract was prepared in 
a way identical to that of the dialyzate of crude thymus extract. BSA was tested 
as  an  antigenic  protein  material,  since  thymus  extracts  were  from  bovine 
source; glucagon was tested as a polypeptide hormone of tool wt (3,460)  similar 
to that  of fraction  C,  the  active principle  of THF.  Finally,  peak  II of DEAE 
Sephadex A-25 anion exchange chromatography was used as a protein control of 
the  same calf thymus origin.  The total lack of activity of all these materials 
gives further strength to the conclusion that the final active product of thymus 
extract has been isolated by the procedures described here. 
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factors deserve further  comment.  Comparison  of the  amino  acid  sequence of 
thymopeietin (23) with the amino acid composition of THF reveals no homology. 
Moreover, thymopoietin is known to induce its effect on pre T cells (prothymo- 
cytes) to express Thy 1,2 antigen, but could not increase the immune competence 
of such lymphocytes (24) while THF confers immunocompetence on target cells 
which  have  already  undergone  some  thymic  processing.  Thymosin  ~1  also 
differs  from  THF  greatly  in  amino  acid  composition  and  cannot  elicit  full 
immunological responsiveness on immature  T  lymphocytes (17).  The material 
isolated  by  Bach  et  al.  (25)  from  pig  serum,  designated  thymic  factor  TF, 
resembles some of the biological properties of THF obtained from calf thymus, 
but until  we determine  the  amino  acid sequence of THF we cannot conclude 
whether or not TF represents a portion of THF. Variation in molecular weights 
or in some of the biological activities studied with these substances may be the 
result of different preparatory procedures which may have altered the confor- 
mation of the molecules, abolishing their activity in some biological assays. 
Summary 
Thymus humoral factor (THF), a thymus hormone which participates in the 
processes  leading  to  acquisition  of immunocompetence  of lymphoid cells  has 
been  isolated  in  our  laboratory  by a  stepwise  gel  filtration  through  various 
Sephadex columns. THF so isolated appears to be a polypeptide of 3,000 mol wt 
which contains approximately 30 amino acid residues. 
Here we have  tested the  biological  activity of THF  fractions  of successive 
degrees of purity upon lymphoid cells from both intact and neonatally thymec- 
tomized mice. 
The lymphoid cell populations were treated with the various THF fractions 
by in vitro incubation  for a  short time and by repeated injection  in vivo. The 
treated cells evidenced increased ability to react in the graft-versus-host assay 
in vivo and in mixed lymphocyte cultures in vitro concomitantly with the rise of 
intracellular  cAMP.  On the other hand no activity whatsoever was shown by 
any  of the  control  materials  tested.  These  bioassays  permitted  isolation  of 
fractions progressively more active than the original crude dialyzate of thymus 
extract tested.  Thus the active peptide component of THF eluted from DEAE 
Sephadex A-25 column was estimated to be 2  x  104-fold more active than  the 
crude dialyzate of thymus extract which served as a starting material. 
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